Jessica A. Walsh

3.2k total citations
101 papers, 1.3k citations indexed

About

Jessica A. Walsh is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Jessica A. Walsh has authored 101 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Rheumatology, 68 papers in Immunology and 36 papers in Hematology. Recurrent topics in Jessica A. Walsh's work include Spondyloarthritis Studies and Treatments (82 papers), Psoriasis: Treatment and Pathogenesis (64 papers) and Rheumatoid Arthritis Research and Therapies (50 papers). Jessica A. Walsh is often cited by papers focused on Spondyloarthritis Studies and Treatments (82 papers), Psoriasis: Treatment and Pathogenesis (64 papers) and Rheumatoid Arthritis Research and Therapies (50 papers). Jessica A. Walsh collaborates with scholars based in United States, United Kingdom and Germany. Jessica A. Walsh's co-authors include Daniel O. Clegg, Kristina Callis Duffin, Yujin Park, Gerald G. Krueger, Gilwan Kim, Atul Deodhar, Marina Magrey, Oluwakayode Adejoro, Joerg Ermann and Maxime Dougados and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Scientific Reports and Annals of the Rheumatic Diseases.

In The Last Decade

Jessica A. Walsh

93 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jessica A. Walsh United States	20	972	808	416	99	81	101	1.3k
Annette Szumski United States	19	896 0.9×	455 0.6×	349 0.8×	45 0.5×	47 0.6×	54	1.1k
Catherine L Shuler United States	13	567 0.6×	662 0.8×	362 0.9×	176 1.8×	32 0.4×	22	957
Arane Thavaneswaran Canada	23	1.6k 1.7×	1.5k 1.9×	814 2.0×	168 1.7×	86 1.1×	40	2.0k
Gregory Ligozio United States	12	590 0.6×	699 0.9×	386 0.9×	167 1.7×	52 0.6×	25	1.3k
Ana Filipa Mourão Portugal	16	534 0.5×	273 0.3×	271 0.7×	29 0.3×	145 1.8×	58	983
Erik Rødevand Norway	15	1.0k 1.0×	368 0.5×	451 1.1×	19 0.2×	30 0.4×	31	1.2k
Clementina López‐Medina Spain	19	817 0.8×	542 0.7×	274 0.7×	13 0.1×	72 0.9×	138	1.0k
M. Hooper United States	11	366 0.4×	311 0.4×	95 0.2×	95 1.0×	51 0.6×	14	816
Adrien Etcheto France	18	491 0.5×	338 0.4×	131 0.3×	17 0.2×	73 0.9×	50	944
Lourdes M. Pérez-Chada United States	14	241 0.2×	319 0.4×	109 0.3×	166 1.7×	38 0.5×	65	762

Countries citing papers authored by Jessica A. Walsh

Since Specialization

Citations

This map shows the geographic impact of Jessica A. Walsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jessica A. Walsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jessica A. Walsh more than expected).

Fields of papers citing papers by Jessica A. Walsh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jessica A. Walsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jessica A. Walsh. The network helps show where Jessica A. Walsh may publish in the future.

Co-authorship network of co-authors of Jessica A. Walsh

This figure shows the co-authorship network connecting the top 25 collaborators of Jessica A. Walsh. A scholar is included among the top collaborators of Jessica A. Walsh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jessica A. Walsh. Jessica A. Walsh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ogdie, Alexis, Soumya M. Reddy, M. Elaine Husni, et al.. (2025). Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. Trials. 26(1). 96–96. 1 indexed citations

Bush, Karen, M. Elaine Husni, Soumya M. Reddy, et al.. (2025). Diverse Treatment Goals in Psoriatic Arthritis: Insights From Participants in the PARC Cohort. Arthritis Care & Research. 77(8). 1007–1013.

Nowell, W. Benjamin, Kelly Gavigan, Kimberly B. Garza, et al.. (2024). Which Educational Topics and Smartphone App Functions Are Prioritized by US Patients With Rheumatic and Musculoskeletal Diseases? A Mixed-Methods Study. The Journal of Rheumatology. 51(9). 904–912. 2 indexed citations

Mease, Philip J., Shannon Ferrante, Natalie J. Shiff, et al.. (2024). Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors. Advances in Therapy. 42(2). 734–751. 1 indexed citations

Walsh, Jessica A., Andrew J. Gawron, Jeffrey R. Curtis, et al.. (2024). Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-naïve patients with inflammatory bowel disease in the Veterans Health Administration. Medicine. 103(37). e39476–e39476.

Tillett, William, Peter Nash, Laura C. Coates, et al.. (2024). Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies. Therapeutic Advances in Musculoskeletal Disease. 16. 1759720X241288071–1759720X241288071.

Walsh, Jessica A., Ruizhi Zhao, Natalie J. Shiff, et al.. (2024). Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors. Drugs - Real World Outcomes. 11(3). 487–499. 3 indexed citations

Baraliakos, Xenofon, et al.. (2024). Comparative Efficacy of Advanced Therapies in the Treatment of Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis as Evaluated by the ASDAS Low Disease Activity Criteria. Rheumatology and Therapy. 11(4). 989–999. 1 indexed citations

Kiewra, Kenneth A., et al.. (2023). Moving Beyond Fulfillment: Wisdom Years Stories of Passion, Perseverance, and Productivity. Educational Psychology Review. 35(1). 20–20. 4 indexed citations

10.

Tillett, William, Joseph F. Merola, Yoshiya Tanaka, et al.. (2023). POS1534 BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDY. Annals of the Rheumatic Diseases. 82. 1130–1131. 3 indexed citations

11.

Walsh, Jessica A., et al.. (2023). Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis. Rheumatology and Therapy. 10(5). 1385–1398. 2 indexed citations

12.

Reddy, Soumya M., M. Elaine Husni, José U. Scher, et al.. (2023). Use of the Bath Ankylosing Spondylitis Disease Activity Index in Patients With Psoriatic Arthritis With and Without Axial Disease. The Journal of Rheumatology. 51(2). 139–143. 5 indexed citations

13.

Reddy, Soumya M., Karen Bush, M. Elaine Husni, et al.. (2023). AB1122 GUSELKUMAB VS GOLIMUMAB IN PSA TNFI-INADEQUATE RESPONDERS (EVOLUTION): FORMULATING A PRAGMATIC PHASE 3B RANDOMIZED TRIAL. Annals of the Rheumatic Diseases. 82. 1791–1791. 1 indexed citations

14.

Gossec, Laure, Jessica A. Walsh, Kaleb Michaud, et al.. (2022). Effect of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey. The Journal of Rheumatology. 49(11). jrheum.211288–jrheum.211288. 11 indexed citations

15.

Gossec, Laure, Jessica A. Walsh, Kaleb Michaud, et al.. (2022). Women With Psoriatic Arthritis Experience Higher Disease Burden Than Men: Findings From a Real-World Survey in the United States and Europe. The Journal of Rheumatology. 50(2). 192–196. 19 indexed citations

16.

Walsh, Jessica A., et al.. (2021). Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis. The Journal of Rheumatology. 48(10). 1559–1565. 10 indexed citations

17.

Ogdie, Alexis, Jessica A. Walsh, Soumya D. Chakravarty, et al.. (2021). The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Clinical Rheumatology. 40(9). 3667–3677. 3 indexed citations

18.

Kiltz, Uta, Désirée van der Heijde, Filip Van den Bosch, et al.. (2020). Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. The Journal of Rheumatology. 48(2). 188–197. 6 indexed citations

19.

Dougados, Maxime, James Cheng‐Chung Wei, Robert Landewé, et al.. (2019). Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Annals of the Rheumatic Diseases. 79(2). 176–185. 86 indexed citations

20.

Maksymowych, Walter P., R. Landewé, Martín Rudwaleit, et al.. (2014). Effect of Certolizumab Pegol Over 48 Weeks in Patients with Axial Spondyloarthritis, including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. The Journal of Rheumatology. 41(7). 1496–1497. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact